US20030100574A1 - Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies - Google Patents
Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies Download PDFInfo
- Publication number
- US20030100574A1 US20030100574A1 US10/294,288 US29428802A US2003100574A1 US 20030100574 A1 US20030100574 A1 US 20030100574A1 US 29428802 A US29428802 A US 29428802A US 2003100574 A1 US2003100574 A1 US 2003100574A1
- Authority
- US
- United States
- Prior art keywords
- gonyautoxin
- composition
- mixture
- saxitoxin
- muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]N1C(=[NH2+])N2C[C@]([2*])([3*])[C@@]([5*])(O)[C@@]23NC(=[NH2+])N[C@@]3([H])[C@@H]1C[4*] Chemical compound [1*]N1C(=[NH2+])N2C[C@]([2*])([3*])[C@@]([5*])(O)[C@@]23NC(=[NH2+])N[C@@]3([H])[C@@H]1C[4*] 0.000 description 3
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- This invention relates to pharmaceutical compositions containing heterocyclic guanidine-type compounds and uses thereof for blocking neuronal transmission. More specifically, this invention relates to tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission.
- Botulin A toxin is a neurotoxin that acts by chemiodenervation, or blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing its contraction for a period of up to 4 months. Applied locally in the face of people, its effect is a facial rejuvenation that appears within 7-10 days after the toxin is applied, and has a duration of approximately 4 months. Botulin A toxin has been used for the treatment of diseases associated with muscular spasm, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis and urinary bladder relaxation.
- Botulin A toxin While Botulin A toxin is effective as a facial rejuvenate, it is an enzyme that is inherently unstable. This instability makes its use and handling complicated and less desirable. In fact, it requires freezing before using and must be used within four hours of opening the container. Because it is an enzyme, Botulin A toxin also generates antibodies that prevent its use in consecutive injections and can also induce an allergic response. In addition, its results are delayed 7-10 days, which is undesirable for patients wanting an immediate result. Accordingly, a need exists for a facial rejuvenate that is stable, fast-acting and that is not an enzyme.
- compositions for interfering with neuronal transmission comprising an effective amount of at least one tricyclic 3,4-propinoperhydropurine are provided.
- preparations for facial rejuvenation comprise an effective amount of the composition of the invention and a facial cream.
- FIG. 1 is an illustration of an application pattern for the treatment of a human face.
- compositions comprising heterocyclic guanidine-type compounds, and more specifically tricyclic 3,4-propinoperhydropurines, can be used for many cosmetic or clinical applications, without any surgery, side effects, allergies, immune rejection or hematoma.
- the compositions of the invention may be used to treat conditions including, but not limited to blepharospasm, strabismus, focal dystonia, sphinceter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing and facial wrinkling.
- muscular relaxation is immediate, usually occurring in less than five minutes.
- compositions of the invention comprise an effective amount of at least one tricyclic 3,4-propinoperhydropurine represented by the following structure:
- R 1 and R 5 are independently H or OH; R 2 and R 3 are independently H or OSO 3 ; and R 4 is independently COONH 2 , OH, H, COONHSO 3 or COOCH 3 ; and a pharmacologically acceptable carrier.
- These tricyclic 3,4-propinoperhydropurines may be purified from dinoflagellates, cyanobacterias and also may be accumulated by highly contaminated mollusks, which are also temporary muscular relaxants when locally injected. Any pharmacologically acceptable carrier may be used, including but not limited to water.
- the compounds of the invention are generally diluted in a solution of acetic acid or 0.09% sodium chloride.
- an effective amount is that amount sufficient to interfere with neuronal transmission by blocking the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of contracted muscles.
- an effective amount of the compositions of the invention may be a 100 to 800 microliter dose of forty units per milliliter solution of tricyclic 3,4-propinoperhydropurines.
- the unit of activity is the amount of the composition of the invention necessary to block the muscular contractions of the crural biceps of a mouse leg for 1.5 to 2.0 hours.
- the compounds of the invention are generally diluted with a 10 mM (millimolar), pH 4 solution of acetic acid.
- the compositions of the invention comprise 40 units per milliliter of a 10 mM, pH 4 solution of acetic acid.
- the pharmaceutical compositions of the invention comprise Saxitoxin.
- the pharmaceutical compositions of the invention comprise Gonyautoxin 2.
- the pharmaceutical compositions of the invention comprise Gonyautoxin 3.
- the pharmaceutical compositions of the invention comprise Gonyautoxin 4.
- the pharmaceutical compositions of the invention comprise Gonyautoxin 5.
- the pharmaceutical compositions of the invention comprise neoSaxtoxin.
- the pharmaceutical compositions of the invention comprise Gonyautoxin 1.
- the pharmaceutical compositions of the invention comprise Decarbamoyl-Saxitoxin.
- TABLE 1 Tricyclic 3,4-propinoperhydropurines Compound R 1 R 2 R 3 R 4 R 5 Saxitoxin H H H COONH 2 OH neoSaxitoxin OH H H COONH 2 OH Decarbamoyl- OH H H OH OH Saxitoxin Gonyautoxin OH H OSO ⁇ 3 COONH 2 OH 1 Gonyautoxin H H OSO ⁇ 3 COONH 2 OH 2 Gonyautoxin H OSO ⁇ 3 H COONH 2 OH 3 Gonyautoxin OH OSO ⁇ 3 H COONH 2 OH 4 Gonyautoxin H H H COONHSO ⁇ 3 OH 5
- the pharmaceutical compositions comprise a mixture of tricyclic 3,4-propinoperhydropurines.
- the compounds are purified and used individually and/or mixed together.
- the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 2, Gonyautoxin 3, and Saxitoxin.
- the pharmaceutical compositions of the invention comprise a mixture of Gonyautoxin 4, Gonyautoxin 1, Gonyautoxin 5, Gonyautoxin 3 and Gonyautoxin 2.
- the pharmaceutical compositions of the invention comprise neoSaxitoxin and Gonyautoxin 2.
- compositions of the invention comprise a mixture of Saxitoxin, neoSaxitoxin, Decarbamoyl-Saxitoxin, Gonyautoxin 3 and Gonyautoxin 2. It should be understood by those of skill in the art that other mixtures and combinations of tricyclic 3,4-propinoperhydropurines are within the scope of this invention.
- the compounds of the invention are used in combination with an effective amount of Botulin A toxin.
- the pharmaceutical compositions of the invention comprise an effective amount of Botulin A toxin and an effective amount of at least one tricyclic 3,4-propinoperhydropurine.
- the combination may be used in any cosmetic or clinical application in which the compounds of the invention, or Botulin A toxin are used, for example, blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal.
- compositions of the invention may be used for many cosmetic and clinical applications including, but not limited to blepharospasm, strabismus, focal dystonia, sphincter relaxation (achalasia and anal fissure), hyperhydrosis, urinary bladder relaxation, muscular spasm-related pain management, muscular spasms, improved wound healing, and facial wrinkle removal.
- the pharmaceutical compositions of the invention are applied locally in the form of preparations.
- an effective amount of the pharmaceutical compositions of the invention are added to a facial cream complete with its coadjuvants.
- these preparations are stable at room temperature, do not require refrigeration, are sterilizable, do not generate antibodies, are not peptide in nature, act immediately, and may be injected repeatedly without any side effects.
- these compounds when applied locally, these compounds carry out their antispasmodic action by blocking the spreading of nervous impulse, or neuronal transmission, by reversibly binding to the sole biological molecular receptor, i.e. the voltage gated sodium channel, present in all neurons and excitable cells. By binding to this channel, there is no entry of sodium to the neuronal cell; depolarization does not occur and, therefore, propagation of the impulse is stopped.
- This action mechanism blocks the presynaptic release of the neurotransmitter acetylcholine in the neuromuscular plate, thus interfering with neuromuscular transmission, paralysing the muscle and preventing it from contracting, or producing a relaxation of muscles contracted by pathological problems.
- This mechanism is particularly efficient for cosmetic purposes, as it does not let some facial muscles contract, all of them associated with and responsible for the formation of wrinkles, thus producing the sought-after effect of facial rejuvenation.
- the pharmaceutical preparations of the invention are applied locally around the muscle that is to be paralysed or prevented from contracting.
- the application should be in amounts of no more than one milliliter in different places around the muscle, particularly around the areas of greatest innervations.
- the unit of activity is the amount of the compositions of the invention necessary to block the contractions of the crural biceps of a mouse leg for 1.5 to 2 hours.
- the preferred dosage rate is 100 to 800 microliters per injected point, depending on the size, irrigation and anatomical location of the muscle, while maintaining a concentration of 20-40 units/milliliter.
- the effect is immediately apparent, generally occuring a maximum of thirty seconds after injection. The maximum effect may be seen within 15 minutes.
- the injection may be accomplished by using a 1 milliliter, tuberculin-type disposable syringe with a twenty-seven to thirty gauge needle. In the case of strabismus, a dose of twenty to forty units in a volume of 50-100 microliters may be injected in the orbicular muscle.
- Use of the pharmaceutical preparations of the invention is limited to individuals over twelve years old. There is no contraindication for pregnant women.
- a photographic record is made of the person to be treated, first with her face resting and relaxed, and then, frowning and producing a maximum facial contraction. The person then places ice on their forehead and on the two lateral zones where the preparation is to be injected. With reference to FIG. 2, the application should follow a specific pattern.
- a volume is injected alongside each black-dot injection point shown in FIG. 2.
- a pharmaceutical composition comprising a (2:1:1 volume/volume) mixture of Gonyautoxin 2, Gonyautoxin 3 and Saxitoxin mixture is applied at a dose of 40 units/milliliter. Each injection is, made with a 1 milliliter, tuberculin-type disposable syringe with a 27-30 gauge needle. After injecting, the point of injection is disinfected with a gauze soaked in bi-alcohol or in any other disinfectant. The total amount required to complete the face treatment is 1.7 milliliters.
- the expected result is an immediate inability to frown and to show lines when the face is resting.
- the person experiences a feeling of facial stretching similar to that felt when applying a facial cream mask.
- ice is applied on the injected zones for five minutes.
- the patient gets used to the feeling of facial stretching.
- the person walks out with no discernible wrinkles, a rejuvenated facial look, no face marks or hematoma, and completely normal.
- the face recovers its normal color within twenty minutes, depending on how relaxed the injected patient has become.
- the whole application procedure takes ten minutes at the most, and produces a very slight pain from the needle and the injected solution. The pain disappears as soon as the syringe is withdrawn.
- the patient may be checked the next day and every fifteen days thereafter. At this dose, the effect lasts for one month. After the first month, the treatment may be repeated as often as necessary.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/338,156 US20060122200A1 (en) | 2001-11-15 | 2006-01-24 | Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
US13/487,722 US9301958B2 (en) | 2001-11-15 | 2012-06-04 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine |
US14/043,634 US8889681B2 (en) | 2001-11-15 | 2013-10-01 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies |
US14/249,914 US8871763B2 (en) | 2001-11-15 | 2014-04-10 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL2764-2001 | 2001-11-15 | ||
CL27642001 | 2001-11-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/338,156 Division US20060122200A1 (en) | 2001-11-15 | 2006-01-24 | Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030100574A1 true US20030100574A1 (en) | 2003-05-29 |
Family
ID=4574581
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/294,288 Abandoned US20030100574A1 (en) | 2001-11-15 | 2002-11-14 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies |
US11/338,156 Abandoned US20060122200A1 (en) | 2001-11-15 | 2006-01-24 | Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
US13/487,722 Expired - Fee Related US9301958B2 (en) | 2001-11-15 | 2012-06-04 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine |
US14/043,634 Expired - Fee Related US8889681B2 (en) | 2001-11-15 | 2013-10-01 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies |
US14/249,914 Expired - Fee Related US8871763B2 (en) | 2001-11-15 | 2014-04-10 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/338,156 Abandoned US20060122200A1 (en) | 2001-11-15 | 2006-01-24 | Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
US13/487,722 Expired - Fee Related US9301958B2 (en) | 2001-11-15 | 2012-06-04 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine |
US14/043,634 Expired - Fee Related US8889681B2 (en) | 2001-11-15 | 2013-10-01 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies |
US14/249,914 Expired - Fee Related US8871763B2 (en) | 2001-11-15 | 2014-04-10 | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
Country Status (18)
Country | Link |
---|---|
US (5) | US20030100574A1 (de) |
EP (1) | EP1443932B1 (de) |
JP (2) | JP5331959B2 (de) |
KR (2) | KR20100135884A (de) |
CN (2) | CN1585642A (de) |
AU (1) | AU2002348370B8 (de) |
BR (1) | BR0214126A (de) |
CA (1) | CA2466697C (de) |
EA (1) | EA006739B1 (de) |
ES (1) | ES2401570T3 (de) |
HU (1) | HUP0402268A2 (de) |
IL (1) | IL161949A0 (de) |
MX (1) | MXPA04004543A (de) |
NO (1) | NO20042475L (de) |
NZ (1) | NZ533309A (de) |
PL (1) | PL370686A1 (de) |
WO (1) | WO2003047589A1 (de) |
ZA (1) | ZA200403765B (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110418A2 (en) | 2004-05-07 | 2005-11-24 | Phytotox Limited | Transdermal administration of phycotoxins |
WO2005110417A1 (en) | 2004-05-07 | 2005-11-24 | Phytotox Limited | Phycotoxins and uses thereof |
WO2006119499A3 (en) * | 2005-05-05 | 2006-12-28 | Phytotox Ltd | Use of phycotoxins in veterinary applications |
WO2010109386A1 (es) * | 2009-03-24 | 2010-09-30 | Proteus S.A. | Método de purificación industrial de ficotoxinas biológicamente activas |
WO2011098539A1 (en) * | 2010-02-10 | 2011-08-18 | Phytotox Limited | Treatment of loss of sense of touch with saxitoxin derivatives |
US10920256B2 (en) | 2016-02-12 | 2021-02-16 | Vestlandets Innovasjonsseiskap AS | Process |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100135884A (ko) * | 2001-11-15 | 2010-12-27 | 마이크로 알제 코포레이션 | 3, 4-프로피온퍼하이드로퓨린을 포함하는 약학 조성물 및 상기 조성물을 이용한 신경 전달의 블로킹 방법 |
JP2009177044A (ja) * | 2008-01-28 | 2009-08-06 | Panasonic Corp | 電気ヒューズ回路 |
EP2459565B1 (de) * | 2009-05-07 | 2018-05-02 | The Board of Trustees of The Leland Stanford Junior University | Saxitoxin derivate, verfahren und zusammensetzungen zum studieren, darstellen und behandeln von schmerz |
JP6313420B2 (ja) * | 2013-03-15 | 2018-04-18 | ザ チルドレンズ メディカル センター コーポレイション | 持続する局所麻酔のためのネオサキシトキシン併用製剤 |
Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957966A (en) * | 1972-05-19 | 1976-05-18 | Gaf Corporation | Stabilized vitamin food coatings |
US5183462A (en) * | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US5504117A (en) * | 1994-05-27 | 1996-04-02 | Neptune Pharmaceutical Corporation | Pharmacologic preparation for the treatment of anal disorders |
US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
US5714468A (en) * | 1994-05-09 | 1998-02-03 | Binder; William J. | Method for reduction of migraine headache pain |
US5837265A (en) * | 1996-03-08 | 1998-11-17 | The Regents Of The University Of California | Chemically-modified clostridiatoxin with improved properties |
US5908746A (en) * | 1995-06-09 | 1999-06-01 | Nisshinbo Industries, Inc. | Method for analyzing biologically active substances |
US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
US6117877A (en) * | 1998-02-27 | 2000-09-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6187756B1 (en) * | 1996-09-05 | 2001-02-13 | The Massachusetts Institute Of Technology | Composition and methods for treatment of neurological disorders and neurodegenerative diseases |
US6261573B1 (en) * | 1998-10-30 | 2001-07-17 | Avant Immunotherapeutics, Inc. | Immunoadjuvants |
US6299893B1 (en) * | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US20010046962A1 (en) * | 1991-09-24 | 2001-11-29 | Allergan Inc. | Method and compositions for the treatment of cerebral palsy |
US6326020B1 (en) * | 1997-05-16 | 2001-12-04 | Children's Medical Center Corporation | Local anesthetic formulations |
US20010053369A1 (en) * | 2000-06-14 | 2001-12-20 | Stephen Donovan | Epilepsy treatment |
US20010053390A1 (en) * | 1999-07-14 | 2001-12-20 | Kaijun Ren | Use of plant extracts for treatment of acne and furuncle |
US20020025327A1 (en) * | 1997-07-15 | 2002-02-28 | University Technology Corporation | Use of neurotoxin therapy for treatment of urologic and related disorders |
US6358926B2 (en) * | 1999-10-13 | 2002-03-19 | Allergan Sales, Inc. | Neurotoxin therapy for inner ear disorders |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
US6416765B1 (en) * | 2000-01-11 | 2002-07-09 | Allergan Sales, Inc. | Neurotoxin therapy for diabetes |
US6432986B2 (en) * | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
US6447787B1 (en) * | 1998-10-27 | 2002-09-10 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
US20020161013A1 (en) * | 2001-04-25 | 2002-10-31 | Wex Medical Intrumentation Co., Ltd. | Method of local anesthesia and analgesia |
US20020176872A1 (en) * | 2000-04-14 | 2002-11-28 | Allergan Sales, Inc. | Pain treatment by peripheral administration of a neurotoxin |
US20020192240A1 (en) * | 2000-10-04 | 2002-12-19 | Allergan Sales, Inc. | Therapy for injured muscles |
US20020198226A1 (en) * | 2001-05-18 | 2002-12-26 | Baoshan Ku | Analgesic composition and method |
US6599906B1 (en) * | 2000-09-18 | 2003-07-29 | Wex Medical Instrumentation Co., Ltd. | Method of local anesthesia and analgesia |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4001413A (en) * | 1973-06-12 | 1977-01-04 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic composition employing saxitoxin |
US4029794A (en) * | 1973-06-12 | 1977-06-14 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic composition |
JP3359193B2 (ja) * | 1995-07-21 | 2002-12-24 | キヤノン株式会社 | 露光装置及びそれを用いたデバイスの製造方法 |
US5721215A (en) * | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
CN1081034C (zh) * | 1997-03-07 | 2002-03-20 | 潘心富 | 一种双胍基氢化嘌呤环类化合物的戒毒药 |
CA2392208A1 (en) * | 1999-11-16 | 2001-05-25 | Johanna C. Vanderspek | Fusion proteins that specifically inhibit protein synthesis in neuronal cells |
US6261572B1 (en) * | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
CN1240702C (zh) | 2000-09-18 | 2006-02-08 | 威克斯医药有限公司 | 高获得率提取替曲朵辛的方法 |
CN1284536C (zh) * | 2000-09-18 | 2006-11-15 | 威克斯医药有限公司 | 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用 |
CN1236773C (zh) * | 2000-11-22 | 2006-01-18 | 南宁枫叶药业有限公司 | 用于镇痛、麻醉或治疗药物依赖性的制剂 |
KR20100135884A (ko) * | 2001-11-15 | 2010-12-27 | 마이크로 알제 코포레이션 | 3, 4-프로피온퍼하이드로퓨린을 포함하는 약학 조성물 및 상기 조성물을 이용한 신경 전달의 블로킹 방법 |
CN1194693C (zh) * | 2002-01-11 | 2005-03-30 | 中国科学院海洋研究所 | 麻痹性贝毒毒素作为制备疗治疼痛病症药物的应用 |
-
2002
- 2002-11-14 KR KR1020107024821A patent/KR20100135884A/ko not_active Application Discontinuation
- 2002-11-14 BR BR0214126-4A patent/BR0214126A/pt active IP Right Grant
- 2002-11-14 IL IL16194902A patent/IL161949A0/xx unknown
- 2002-11-14 PL PL02370686A patent/PL370686A1/xx not_active Application Discontinuation
- 2002-11-14 HU HU0402268A patent/HUP0402268A2/hu unknown
- 2002-11-14 US US10/294,288 patent/US20030100574A1/en not_active Abandoned
- 2002-11-14 NZ NZ533309A patent/NZ533309A/xx not_active IP Right Cessation
- 2002-11-14 AU AU2002348370A patent/AU2002348370B8/en not_active Ceased
- 2002-11-14 EA EA200400670A patent/EA006739B1/ru not_active IP Right Cessation
- 2002-11-14 KR KR10-2004-7007435A patent/KR20040066816A/ko not_active Application Discontinuation
- 2002-11-14 CN CNA028226429A patent/CN1585642A/zh active Pending
- 2002-11-14 CA CA2466697A patent/CA2466697C/en not_active Expired - Lifetime
- 2002-11-14 CN CN201110208308.1A patent/CN102349914B/zh not_active Expired - Fee Related
- 2002-11-14 EP EP02782296A patent/EP1443932B1/de not_active Expired - Lifetime
- 2002-11-14 WO PCT/US2002/036412 patent/WO2003047589A1/en active Application Filing
- 2002-11-14 JP JP2003548844A patent/JP5331959B2/ja not_active Expired - Fee Related
- 2002-11-14 MX MXPA04004543A patent/MXPA04004543A/es active IP Right Grant
- 2002-11-14 ES ES02782296T patent/ES2401570T3/es not_active Expired - Lifetime
-
2004
- 2004-05-17 ZA ZA2004/03765A patent/ZA200403765B/en unknown
- 2004-06-14 NO NO20042475A patent/NO20042475L/no not_active Application Discontinuation
-
2006
- 2006-01-24 US US11/338,156 patent/US20060122200A1/en not_active Abandoned
-
2010
- 2010-10-01 JP JP2010223330A patent/JP2011068649A/ja active Pending
-
2012
- 2012-06-04 US US13/487,722 patent/US9301958B2/en not_active Expired - Fee Related
-
2013
- 2013-10-01 US US14/043,634 patent/US8889681B2/en not_active Expired - Fee Related
-
2014
- 2014-04-10 US US14/249,914 patent/US8871763B2/en not_active Expired - Fee Related
Patent Citations (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957966A (en) * | 1972-05-19 | 1976-05-18 | Gaf Corporation | Stabilized vitamin food coatings |
US5183462A (en) * | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
US5298019A (en) * | 1990-08-21 | 1994-03-29 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
US20010046962A1 (en) * | 1991-09-24 | 2001-11-29 | Allergan Inc. | Method and compositions for the treatment of cerebral palsy |
US20020142010A1 (en) * | 1991-09-24 | 2002-10-03 | Allergan | Method and compositions for the treatment of cerebral palsy |
US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US5674205A (en) * | 1993-08-26 | 1997-10-07 | The Johns Hopkins University | Device for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US5714468A (en) * | 1994-05-09 | 1998-02-03 | Binder; William J. | Method for reduction of migraine headache pain |
US5504117A (en) * | 1994-05-27 | 1996-04-02 | Neptune Pharmaceutical Corporation | Pharmacologic preparation for the treatment of anal disorders |
US5908746A (en) * | 1995-06-09 | 1999-06-01 | Nisshinbo Industries, Inc. | Method for analyzing biologically active substances |
US5837265A (en) * | 1996-03-08 | 1998-11-17 | The Regents Of The University Of California | Chemically-modified clostridiatoxin with improved properties |
US6187756B1 (en) * | 1996-09-05 | 2001-02-13 | The Massachusetts Institute Of Technology | Composition and methods for treatment of neurological disorders and neurodegenerative diseases |
US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
US6326020B1 (en) * | 1997-05-16 | 2001-12-04 | Children's Medical Center Corporation | Local anesthetic formulations |
US20020025327A1 (en) * | 1997-07-15 | 2002-02-28 | University Technology Corporation | Use of neurotoxin therapy for treatment of urologic and related disorders |
US6432986B2 (en) * | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
US6117877A (en) * | 1998-02-27 | 2000-09-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
US6447787B1 (en) * | 1998-10-27 | 2002-09-10 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
US20030036502A1 (en) * | 1998-10-27 | 2003-02-20 | Gassner Holger G. | Methods for enhancing wound healing |
US6261573B1 (en) * | 1998-10-30 | 2001-07-17 | Avant Immunotherapeutics, Inc. | Immunoadjuvants |
US20010053390A1 (en) * | 1999-07-14 | 2001-12-20 | Kaijun Ren | Use of plant extracts for treatment of acne and furuncle |
US6358926B2 (en) * | 1999-10-13 | 2002-03-19 | Allergan Sales, Inc. | Neurotoxin therapy for inner ear disorders |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6416765B1 (en) * | 2000-01-11 | 2002-07-09 | Allergan Sales, Inc. | Neurotoxin therapy for diabetes |
US20020176872A1 (en) * | 2000-04-14 | 2002-11-28 | Allergan Sales, Inc. | Pain treatment by peripheral administration of a neurotoxin |
US20040018213A1 (en) * | 2000-04-14 | 2004-01-29 | Allergan Inc. | Pain treatment by peripheral administration of a neurotoxin |
US20040028706A1 (en) * | 2000-04-14 | 2004-02-12 | Aoki Kei Roger | Neuralgia pain treatment by peripheral administration of a neurotoxin |
US6299893B1 (en) * | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US20010053369A1 (en) * | 2000-06-14 | 2001-12-20 | Stephen Donovan | Epilepsy treatment |
US6599906B1 (en) * | 2000-09-18 | 2003-07-29 | Wex Medical Instrumentation Co., Ltd. | Method of local anesthesia and analgesia |
US20020192240A1 (en) * | 2000-10-04 | 2002-12-19 | Allergan Sales, Inc. | Therapy for injured muscles |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
US20020161013A1 (en) * | 2001-04-25 | 2002-10-31 | Wex Medical Intrumentation Co., Ltd. | Method of local anesthesia and analgesia |
US20020198226A1 (en) * | 2001-05-18 | 2002-12-26 | Baoshan Ku | Analgesic composition and method |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1802250A4 (de) * | 2004-05-07 | 2008-07-02 | Phytotox Ltd | Verfahren zur behandlung von wunden mit gonyautoxinen |
AU2005244116B8 (en) * | 2004-05-07 | 2011-03-31 | Algenis Spa | Methods of treating wounds with gonyautoxins |
WO2005110275A1 (en) | 2004-05-07 | 2005-11-24 | Phytotox Limited | Methods of treating wounds with gonyautoxins |
EP1796676A4 (de) * | 2004-05-07 | 2008-06-25 | Phytotox Ltd | Transdermale verabreichung von phycotoxinen |
EP1796676A2 (de) * | 2004-05-07 | 2007-06-20 | Phytotox Limited | Transdermale verabreichung von phycotoxinen |
EP1802250A1 (de) * | 2004-05-07 | 2007-07-04 | Phytotox Limited | Verfahren zur behandlung von wunden mit gonyautoxinen |
EP1824488A1 (de) * | 2004-05-07 | 2007-08-29 | Phytotox Limited | Phycotoxine und verwendungen damit |
US20070280970A1 (en) * | 2004-05-07 | 2007-12-06 | Phytotox Limited | Methods of Treating Wounds With Gonyautoxins |
US20080021051A1 (en) * | 2004-05-07 | 2008-01-24 | Phytotox Limited | Phycotoxins and Uses Thereof |
US20080045553A1 (en) * | 2004-05-07 | 2008-02-21 | Phytotox Limited | Transdermal Administration of Phycotoxins |
EP1824488A4 (de) * | 2004-05-07 | 2008-07-02 | Phytotox Ltd | Phycotoxine und verwendungen damit |
US8377951B2 (en) | 2004-05-07 | 2013-02-19 | Phytotox Limited | Transdermal administration of phycotoxins |
AU2005244116B2 (en) * | 2004-05-07 | 2011-03-03 | Algenis Spa | Methods of treating wounds with gonyautoxins |
AU2005244105B2 (en) * | 2004-05-07 | 2011-10-06 | Algenis Spa | Phycotoxins and uses thereof |
WO2005110418A2 (en) | 2004-05-07 | 2005-11-24 | Phytotox Limited | Transdermal administration of phycotoxins |
AU2005244096B2 (en) * | 2004-05-07 | 2011-03-17 | Algenis Spa | Transdermal administration of phycotoxins |
WO2005110417A1 (en) | 2004-05-07 | 2005-11-24 | Phytotox Limited | Phycotoxins and uses thereof |
AU2005244116C1 (en) * | 2004-05-07 | 2011-09-29 | Algenis Spa | Methods of treating wounds with gonyautoxins |
WO2006119499A3 (en) * | 2005-05-05 | 2006-12-28 | Phytotox Ltd | Use of phycotoxins in veterinary applications |
WO2010109386A1 (es) * | 2009-03-24 | 2010-09-30 | Proteus S.A. | Método de purificación industrial de ficotoxinas biológicamente activas |
WO2011098539A1 (en) * | 2010-02-10 | 2011-08-18 | Phytotox Limited | Treatment of loss of sense of touch with saxitoxin derivatives |
US9107925B2 (en) | 2010-02-10 | 2015-08-18 | Phytotox Limited | Sodium channel blocker for treatment of loss of superficial sensitivity |
US11566271B2 (en) | 2016-02-12 | 2023-01-31 | Vestlandets Innovasjonsseiskap AS | Processes to make neosaxitoxin and analogues thereof |
US10920256B2 (en) | 2016-02-12 | 2021-02-16 | Vestlandets Innovasjonsseiskap AS | Process |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8889681B2 (en) | Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm-related clinical pathologies | |
US6197830B1 (en) | Method for achieving relief from sympathetically mediated pain | |
AU2005244096B2 (en) | Transdermal administration of phycotoxins | |
US20080044439A1 (en) | Compositions and Methods for Preventing and Treating Skin and Hair Conditions | |
US20070148118A1 (en) | Cosmetic composition for skin application suitable for relaxing expression wrinkles | |
EP2977058A1 (de) | Verfahren zur behandlung adhäsiver capsulitis | |
WO2011098539A1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
RU2289417C1 (ru) | Способ биологического омоложения кожи | |
WO2014204090A1 (ko) | 필러와 보틀리눔 독소를 포함하는 피부 주름, 노화 개선 또는 신경근육 관련 질환 치료용 조성물 | |
EP1135094B1 (de) | Verfahren zur verminderung des haarausfalls und förderung des haarwiederwachstums | |
CA2356543A1 (en) | Process and composition for improving the growth of human head hair | |
BRPI0214126B1 (pt) | Composição farmacêutica para interferir na transmissão neuronal, e, preparação para o rejuvenescimento facial | |
Bernard et al. | Randomized, open-labelled comparison between an idoxuridine 10% gel and acyclovir 5% cream in recurrent herpes labialis. | |
Andre | An easy and effective local anaesthesia for treating palmar hyperhidrosis with botulinum toxin injections: the Cry-ac system. | |
JPS60208907A (ja) | 毛髪成長刺激剤 | |
West | properly and after being worn for days, are unlikely to prove disturbing. They do not interfere with ordinary con¬ | |
KR20000063326A (ko) | 표면마취 효과를 가진 액제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PHYTOTOX S.A., CHILE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WILSON, NESTOR ANTONIO LAGOS;REEL/FRAME:013686/0331 Effective date: 20021114 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |